S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:MNTAMomenta Pharmaceuticals Stock Price, Forecast & News

$28.75
+0.84 (+3.01 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$27.45
Now: $28.75
$28.93
50-Day Range
$27.91
MA: $32.96
$39.27
52-Week Range
$11.29
Now: $28.75
$39.88
Volume1.76 million shs
Average Volume1.20 million shs
Market Capitalization$3.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Read More
Momenta Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MNTA
CUSIP60877T10
Phone617-491-9700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.87 million
Book Value$4.59 per share

Profitability

Net Income$-290,050,000.00
Net Margins-994.16%

Miscellaneous

Employees131
Market Cap$3.42 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$28.75
+0.84 (+3.01 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

How has Momenta Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Momenta Pharmaceuticals' stock was trading at $26.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MNTA stock has increased by 8.9% and is now trading at $28.75.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Momenta Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Momenta Pharmaceuticals
.

When is Momenta Pharmaceuticals' next earnings date?

Momenta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Momenta Pharmaceuticals
.

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) EPS for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.06. Momenta Pharmaceuticals had a negative net margin of 994.16% and a negative return on equity of 80.37%.
View Momenta Pharmaceuticals' earnings history
.

What price target have analysts set for MNTA?

10 equities research analysts have issued 1 year price objectives for Momenta Pharmaceuticals' shares. Their forecasts range from $29.00 to $57.00. On average, they expect Momenta Pharmaceuticals' stock price to reach $43.44 in the next year. This suggests a possible upside of 51.1% from the stock's current price.
View analysts' price targets for Momenta Pharmaceuticals
.

Has Momenta Pharmaceuticals been receiving favorable news coverage?

Press coverage about MNTA stock has trended extremely negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Momenta Pharmaceuticals earned a news impact score of -4.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
View the latest news about Momenta Pharmaceuticals
.

Are investors shorting Momenta Pharmaceuticals?

Momenta Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 8,150,000 shares, an increase of 31.7% from the June 15th total of 6,190,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 7.0 days.
View Momenta Pharmaceuticals' Short Interest
.

Who are some of Momenta Pharmaceuticals' key competitors?

What other stocks do shareholders of Momenta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Amicus Therapeutics (FOLD), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD), Inovio Pharmaceuticals (INO), Pfizer (PFE) and GW Pharmaceuticals PLC- (GWPH).

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the following people:
  • Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 59)
  • Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 52)
  • Dr. Santiago Arroyo, Chief Medical Officer & Sr. VP of Devel. (Age 59)
  • Mr. Bruce A. Leicher, Consultant (Age 63)
  • Mr. Scott M. Storer, Consultant

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Who are Momenta Pharmaceuticals' major shareholders?

Momenta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Bank of New York Mellon Corp (1.13%), Viking Global Investors LP (0.80%), Principal Financial Group Inc. (0.78%), Healthcare of Ontario Pension Plan Trust Fund (0.55%) and Jennison Associates LLC (0.52%). Company insiders that own Momenta Pharmaceuticals stock include Agnieszka Cieplinska, Alejandra Carvajal, Anthony M Manning, Bruce Downey, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Georges Gemayel, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo, Steven C Gilman and Young Kwon.
View institutional ownership trends for Momenta Pharmaceuticals
.

Which major investors are selling Momenta Pharmaceuticals stock?

MNTA stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Peregrine Capital Management LLC, AJO LP, Prudential Financial Inc., UBS Group AG, AlphaCrest Capital Management LLC, Russell Investments Group Ltd., and Virtus ETF Advisers LLC. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Agnieszka Cieplinska, Alejandra Carvajal, Anthony M Manning, Craig A Wheeler, Elizabeth Stoner, Georges Gemayel, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo, Steven C Gilman, and Young Kwon.
View insider buying and selling activity for Momenta Pharmaceuticals
.

Which major investors are buying Momenta Pharmaceuticals stock?

MNTA stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Healthcare of Ontario Pension Plan Trust Fund, FIL Ltd, Candriam Luxembourg S.C.A., Federated Hermes Inc., Asymmetry Capital Management L.P., ClariVest Asset Management LLC, and FMR LLC.
View insider buying and selling activity for Momenta Pharmaceuticals
.

How do I buy shares of Momenta Pharmaceuticals?

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of MNTA stock can currently be purchased for approximately $28.75.

How big of a company is Momenta Pharmaceuticals?

Momenta Pharmaceuticals has a market capitalization of $3.42 billion and generates $23.87 million in revenue each year. The biotechnology company earns $-290,050,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Momenta Pharmaceuticals employs 131 workers across the globe.

What is Momenta Pharmaceuticals' official website?

The official website for Momenta Pharmaceuticals is www.momentapharma.com.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.